Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function.

Biomarker research

Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, Liu D.
PMID: 24991411
Biomark Res. 2014 Jun 23;2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014.

ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) remains the most commonly used front-line therapy for Hodgkin lymphoma. However, atypical and extranodal presentations present challenges to initial therapy, especially in the presence of renal and liver failure. We hereby present...

Cite
Thakar K, Novero A, Das A, et al. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res. 2014;2:12doi: 10.1186/2050-7771-2-12.
Thakar, K., Novero, A., Das, A., Lisinschi, A., Mehta, B., Ahmed, T., & Liu, D. (2014). CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomarker research, 212. https://doi.org/10.1186/2050-7771-2-12
Thakar, Keyur, et al. "CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function." Biomarker research vol. 2 (2014): 12. doi: https://doi.org/10.1186/2050-7771-2-12
Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, Liu D. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res. 2014 Jun 23;2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014. PMID: 24991411; PMCID: PMC4078319.
Copy Download .nbib Format: NLM
Correction: Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis.

Translational psychiatry

Hieronymus F, Lisinski A, Eriksson E, Østergaard SD.
PMID: 33963172
Transl Psychiatry. 2021 May 07;11(1):274. doi: 10.1038/s41398-021-01403-w.

No abstract available.

Cite
Hieronymus F, Lisinski A, Eriksson E, et al. Correction: Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis. Transl Psychiatry. 2021;11(1):274doi: 10.1038/s41398-021-01403-w.
Hieronymus, F., Lisinski, A., Eriksson, E., & Østergaard, S. D. (2021). Correction: Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis. Translational psychiatry, 11(1), 274. https://doi.org/10.1038/s41398-021-01403-w
Hieronymus, Fredrik, et al. "Correction: Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis." Translational psychiatry vol. 11,1 (2021): 274. doi: https://doi.org/10.1038/s41398-021-01403-w
Hieronymus F, Lisinski A, Eriksson E, Østergaard SD. Correction: Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis. Transl Psychiatry. 2021 May 07;11(1):274. doi: 10.1038/s41398-021-01403-w. PMID: 33963172; PMCID: PMC8105385.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries